IGM BIOSCIENCES INC (IGMS) Stock Fundamental Analysis
USA - NASDAQ:IGMS - US4495851085 - Common Stock
1.27 USD
-0.03 (-2.31%)
1.28 USD
+0.01 (+0.79%)
We assign a fundamental rating of 3 out of 10 to IGMS. IGMS was compared to 533 industry peers in the Biotechnology industry. While IGMS has a great health rating, there are worries on its profitability. IGMS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IGMS had negative earnings in the past year.
IGMS had a negative operating cash flow in the past year.
In the past 5 years IGMS always reported negative net income.
IGMS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -49.53%, IGMS is in line with its industry, outperforming 51.00% of the companies in the same industry.
With a decent Return On Equity value of -52.48%, IGMS is doing good in the industry, outperforming 64.85% of the companies in the same industry.
With an excellent Return On Invested Capital value of 7.99%, IGMS belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.53% | ||
| ROE | -52.48% | ||
| ROIC | 7.99% |
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IGMS has a better Operating Margin (7.04%) than 91.62% of its industry peers.
IGMS does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.04% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IGMS is destroying value.
The number of shares outstanding for IGMS has been increased compared to 1 year ago.
Compared to 5 years ago, IGMS has more shares outstanding
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.33, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
IGMS has a Altman-Z score (-2.33) which is in line with its industry peers.
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.33 |
ROIC/WACC0.82
WACC9.76%
2.3 Liquidity
IGMS has a Current Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.66, IGMS belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
IGMS has a Quick Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.66, IGMS belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.66 | ||
| Quick Ratio | 17.66 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 85.01% over the past year.
The Revenue has grown by 4881.11% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%
3.2 Future
The Earnings Per Share is expected to grow by 11.78% on average over the next years. This is quite good.
Based on estimates for the next years, IGMS will show a quite strong growth in Revenue. The Revenue will grow by 18.08% on average per year.
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -5.77 |
4.3 Compensation for Growth
IGMS's earnings are expected to grow with 19.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.79%
EPS Next 3Y19.3%
5. Dividend
5.1 Amount
IGMS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.27
-0.03 (-2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners53.06%
Inst Owner Change-99.57%
Ins Owners2.48%
Ins Owner Change-1161.28%
Market Cap76.57M
Revenue(TTM)145.05M
Net Income(TTM)-53.00M
Analysts48.89
Price Target1.27 (0%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)297.19%
Min EPS beat(2)-21.95%
Max EPS beat(2)616.34%
EPS beat(4)2
Avg EPS beat(4)147.4%
Min EPS beat(4)-23.77%
Max EPS beat(4)616.34%
EPS beat(8)5
Avg EPS beat(8)-167.29%
EPS beat(12)9
Avg EPS beat(12)-109.67%
EPS beat(16)12
Avg EPS beat(16)-83.61%
Revenue beat(2)1
Avg Revenue beat(2)2105.97%
Min Revenue beat(2)-84.23%
Max Revenue beat(2)4296.17%
Revenue beat(4)3
Avg Revenue beat(4)1075.96%
Min Revenue beat(4)-84.23%
Max Revenue beat(4)4296.17%
Revenue beat(8)3
Avg Revenue beat(8)515.32%
Revenue beat(12)5
Avg Revenue beat(12)338.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)37.73%
EPS NQ rev (3m)-16%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.76 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | -5.77 |
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-2.62
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS2.41
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.53% | ||
| ROE | -52.48% | ||
| ROCE | 10.11% | ||
| ROIC | 7.99% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 7.04% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 29.58% | ||
| Cap/Sales | 1.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.66 | ||
| Quick Ratio | 17.66 | ||
| Altman-Z | -2.33 |
F-Score5
WACC9.76%
ROIC/WACC0.82
Cap/Depr(3y)125.69%
Cap/Depr(5y)474.33%
Cap/Sales(3y)578.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%
EBIT growth 1Y104.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.17%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y19.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.46%
OCF growth 3YN/A
OCF growth 5YN/A
IGM BIOSCIENCES INC / IGMS FAQ
Can you provide the ChartMill fundamental rating for IGM BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to IGMS.
What is the valuation status for IGMS stock?
ChartMill assigns a valuation rating of 0 / 10 to IGM BIOSCIENCES INC (IGMS). This can be considered as Overvalued.
How profitable is IGM BIOSCIENCES INC (IGMS) stock?
IGM BIOSCIENCES INC (IGMS) has a profitability rating of 2 / 10.
What is the financial health of IGM BIOSCIENCES INC (IGMS) stock?
The financial health rating of IGM BIOSCIENCES INC (IGMS) is 7 / 10.